A Diabetes Drug Delivery Deal
By
Brian Orelli
June 24, 2008
|
When deciding whether to approve a drug, the FDA only cares whether it's safe and effective. But once the drug hits the market, a third characteristic -- how the drug is taken -- helps determine whether it obtains blockbuster status.
Most type 2 diabetes patients have started out on oral medications like Bristol-Myers Squibb's (NYSE: BMY) Glucophage -- available as generic metformin -- then progressed to injectable insulin. Newer medications like Merck's (NYSE: MRK) Januvia sought to put off the inevitable needle pokes by giving patients another oral therapy before heading on to insulin.
Then there's Amylin Pharmaceuticals' (Nasdaq: AMLN) Byetta. An analog of the hormone GLP-1, this wonder drug improves glucose levels and helps diabetics shed pounds -- but it has one big problem. Byetta aims to help patients avoid using insulin, but still results in two needle pokes a day, which has put a damper on its sales. Novo Nordisk (NYSE: NVO) has tried to best Byetta by developing a competing GLP-1 analog that only needs to be injected once a day.
If one injection a day is better than two, then one injection per week should be seven times better. That's what Amylin and marketing partner Eli Lilly (NYSE: LLY) are doing with Byetta. Using Alkermes' (Nasdaq: ALKS) microsphere technology, the once-weekly Byetta looked good in trials, although it's still more than a year away from being on the market.
Novo Nordisk isn't waiting idly by to be outdone by once-weekly Byetta, though. The diabetes expert announced yesterday that it's taking drug delivery full circle by attempting to make an oral version of GLP-1-like drugs. It won't be easy; if it were, Amylin, Novo Nordisk, and others would have started there in the first place. But Novo Nordisk thinks it can use Emisphere Technologies' (Nasdaq: EMIS) eligen technology to carry GLP-1 drugs across the membranes of the gut and into the bloodstream.
Hold on to your seat, Fools. The GLP-1 drug wars are going to deliver one bumpy ride.
“The Next Great Investment”… That’s how a top global investor describes India’s potential. On Nov. 28, The Motley Fool’s Tim Hanson returns to India to prove it. Follow along in real time and get his TOP pick first (Hanson returned from China in July with a stock that’s up 169%!). Enter email below.